Nabi – Nanomédecine, Biologie Extracellulaire, Intégratome et Innovations en Santé
NABI Laboratory: Mission and Objectives
The NABI Laboratory (Nanomedicine, Extracellular Biology, Integratome, and Health Innovations), established on January 1, 2025, by Université Paris Cité, CNRS, and INSERM, aims to develop next-generation therapeutic approaches and make them accessible to the greatest number of patients.
Through interdisciplinary research and our technology accelerator, the IVETh Bioproduction and Biotherapy Integrator, our ambition is to democratize biotherapies and de-risk their bioproduction.
Live/dead assay of fibroblasts on beads (from Léa Jabbour)
Schematic of an antero-cutaneous fistula (by Anna Sebbagh)
Co-culture of cholangiocarcinoma cells (GFP) and fibroblasts (mCherry) exposed to iron oxide nanoflowers decorated with gold NPs (by Sonia Becharef)
Schematic of an intestine affected by Crohn disease (by Anna Sebbagh)
Schematic of mesenchymal stem cells (by Anna Sebbagh)
Locomotion pattern of C. elegans (BPJ cover, JM Di Meglio)
Schematic of a mixed lymphocyte reaction assay (by Anna Sebbagh)
Schematic of an extracellular vesicle (by Anna Sebbagh)
Schematic of Atomic Force Microscopy (AFM) on polymers (by JM Di Meglio)
TEM on fibroblast exposed to Gold salts (by Giulio Avveduto).
Our Objectives
Understanding the role and fate of exogenous and endogenous nanoparticles in the body
- Investigate their properties, transformations, and impact within the organism.
- Decipher intercellular communication mechanisms involving biological nanoparticles (extracellular vesicles, viral particles, mitochondria, etc.).
Developing innovative (bio)therapies
- Leverage biological nanoparticles as therapeutic vectors in nanomedicine or as alternatives to cell therapies.
- Optimize immunotherapies and other precision treatments through external physical control.
- Overcome treatment resistance mechanisms with innovative delivery strategies.
Integrating bioproduction challenges
- Develop robust, controlled, and eco-friendly processes for the production of biological nanoparticles for therapeutic use.
- Ensure the reproducibility, safety, and scalability of manufacturing processes through AI-driven optimization for industrial and clinical transfer.
- Develop quality control methods at the nanometric scale.
Facilitating the transfer of innovations to clinical applications
- Transform scientific breakthroughs into concrete medical applications.
- Bridge the gap between fundamental research and clinical trials to directly benefit patients.
Promoting an interdisciplinary and collaborative approach
- Bring together researchers in engineering, physics, biology, medicine, chemistry, and AI for an integrated approach.
- Develop partnerships with academic institutions and industry to accelerate innovation.
Addressing global and planetary health challenges
- Contribute to disease prevention and treatment by developing safer, more effective, and more targeted therapies.
- Integrate environmental and ethical considerations into the development of nanomedicines and bioprocesses.
The NABI Laboratory is committed to pushing the boundaries of nanomedicine to make biotherapies accessible to all and to secure their large-scale production.
News
Une étude d’ampleur sur l’effet des nanoparticules
Depuis quelques années, la chimie, la pharmacie, l’agriculture, l’agroalimentaire, les cosmétiques etc. se tournent de plus en plus vers des préparations contenant des nanoparticules. La présence croissante de ces nanoparticules dans notre environnement soulève des...
Financial supports
